New hope for hard-to-treat cancers with rare gene mutations
NCT ID NCT06357988
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 25 times
Summary
This study tests a drug called vismodegib in people with advanced or treatment-resistant cancers (solid tumors, lymphoma, or multiple myeloma) that have specific changes in the SMO or PTCH1 genes. The drug blocks a protein that helps cancer grow. The goal is to see if the drug can shrink tumors or stop them from growing for at least 6 months. About 34 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.